Who is sponsoring ATTENTION?

ATTENTION is sponsored by Kyowa Kirin Co., Ltd..

What condition does ATTENTION study?

ATTENTION studies Non-small-cell Lung Cancer.

What drugs are being tested in ATTENTION?

Interventions: ARQ 197 and Erlotinib, Placebo and Erlotinib.

What is the status of ATTENTION?

ATTENTION is currently TERMINATED.

Last reviewed 2016-12-05 · How we verify

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer With Wild-type Epidermal Growth Factor Receptor (ATTENTION)

NCT01377376 Phase 3 TERMINATED

The primary objective of this study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival (OS) compared to erlotinib monotherapy in subjects with locally advanced or metastatic non-squamous NSCLC with wild-type EGFR who have received 1 or 2 prior systemic anti-cancer therapies in the Intent-to-Treat (ITT) population.

Details

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 3
Status	TERMINATED
Start date	2011-07

Conditions

Non-small-cell Lung Cancer

Interventions

ARQ 197 and Erlotinib
Placebo and Erlotinib

Primary outcomes

Overall survival

Countries

Japan